Combining information from multiple data sources to create multivariable risk models: Illustration and preliminary assessment of a new method

Journal of Biomedicine and Biotechnology

Volumn 2005, Issue 2, 2005, Pages 113-123

  Samsa, Greg ^a   Hu, Guizhou ^b   Root, Martin ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b BioSignia Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COHORT ANALYSIS; EMPIRICISM; HIGH RISK POPULATION; INFORMATION PROCESSING; LINEAR REGRESSION ANALYSIS; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL MODEL; TECHNIQUE;

EID: 17844388271     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/JBB.2005.113     Document Type: Article

References (30)

1. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1-30.
2. Egger M, Schneider M, Smith GD. Spurious precision? Meta-analysis of observational studies. BMJ. 1998;316(7125):140-144.
3. Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C. Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol. 1999;28(1):1-9.
4. Greenland S. Invited commentary: a critical look at some popular meta-analytic methods. Am J Epidemiol. 1994;140(3):290-296.
5. Mosteller F, Colditz GA. Understanding research synthesis (meta-analysis). Ann. Rev. Public Health. 1996;17:1-23.
6. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323(7304):101-105.
7. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 1993;118(12):956- 963.
8. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ. 2003;327(7407):128-132.
9. Vincent JL, Dubois MJ, Navickis RJ, Wilkes MM. Hypoalbuminemia in acute illness: is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials. Ann Surg. 2003;237(3):319-334.
10. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279(18):1477-1482.
11. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med. 2002;21(4):589-624.
12. Nam IS, Mengersen K, Garthwaite P. Multivariate meta-analysis. Stat Med. 2003;22(14):2309-2333.
13. Arends LR, Vokó Z, Stijnen T. Combining multiple outcome measures in a meta-analysis: an application. Stat Med. 2003;22(8):1335-1353.
14. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278(16):1349-1356.
15. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291(2):210-215.
16. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-1886.
17. Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91(18):1541-1548.
18. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371-1388.
19. Anderson S, Ahnn S, Duff K. NSABP Breast Cancer Prevention Trial Risk Assessment Program (Version 2). NSABP Biostatistical. Center Technical Report. 1992.
20. Anderson KM, Wilson PW, Odell PM. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83(1):356-362.
21. Laurier D, Nguyen PC, Gazelles B, Segond P. Estimation of CHD risk in a French working population using a modified Framingham model. The PCV-METRA Group. J Clin Epidemiol. 1994;47(12):1353-1364.
22. Menotti A, Land M, Puddu PE, Kromhout D. Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chart. Heart. 2000;84(3):238-244.
23. D'Agostino R, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180-187.
24. Marrugat J, D'Agostino R, Sullivan L. Adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health. 2003;57(8):634-638.
25. Matchar DB, Samsa GP, Matthews JR, et al. The Stroke Prevention Policy Model: linking evidence and clinical decisions. Ann Intern Med. 1997;127:704-711.
26. Samsa GP, Reutter RA, Parmigiani G, et al. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. J Clin Epidemiol. 1999;52(3):259-271.
27. Pigott TD. Missing predictors in models of effect size. Eval Health Prof. 2001;24(3):277-307.
28. Zhao LP, Lipsitz S, Lew D. Regression analysis with missing covariate data using estimating equation. Biometrics. 1996;52(4):1165-1182.
29. Steyerberg EW, Eijkemans MJ, van Houwelingen JC, Lee KL, Habbema JD. Prognostic models based on literature and individual patient data in logistic regression analysis. Stat Med. 2000;19(2):141-160.
30. Draper N, Smith H. Applied Regression Analysis. 2nd ed. New York, NY: John Wiley & Sons. 1981.